Target intelligence / Profile preview

DnaJ heat shock protein family member C13 (DNAJC13)

Target
DNAJC13
Molecular classification
Heat shock protein (Hsp40 family, co-chaperone), Endosomal trafficking regulator, Other (molecular chaperone co-factor)
01

Overview

DnaJ heat shock protein family member C13 (DNAJC13) encodes a large co-chaperone protein primarily localized to endosomes, where it regulates membrane recycling, clathrin-mediated endocytosis, and cargo sorting via interactions with Hsc70, the retromer/SNX1 complex, and components of the actin cytoskeleton. Its conserved J-domain allows binding to Hsp70 chaperones, stimulating ATP hydrolysis required for protein refolding and quality control. DNAJC13 is central to maintaining endosomal membrane dynamics and autophagic flux, crucial for neuronal proteostasis. Pathogenic mutations, such as N855S, disrupt endosomal trafficking and protein recycling, causing α-synuclein accumulation, and are genetically linked to familial Parkinson’s disease and plausibly essential tremor. DNAJC13 is not currently a direct therapeutic target, but its pathogenic role and critical cellular functions make it significant in the context of neurodegenerative disease biology.

Other names
Receptor-mediated endocytosis 8RME-8PARK21KIAA0678DnaJ (Hsp40) homolog, subfamily C, member 13DnaJ domain-containing protein RME-8Required for receptor-mediated endocytosis 8
02

Mechanism of action

Not directly targeted by drugs; disease mutations have a toxic gain-of-function affecting endosomal trafficking, α-synuclein metabolism, and autophagy

03

Biological functions

Endosomal membrane traffickingClathrin-mediated endocytosisRegulation of membrane recycling and cargo sortingProtein folding via Hsp70/Hsc70 interactionProtein quality controlModulation of autophagyRegulation of actin cytoskeleton organization in endosomes
04

Disease associations

Neurodegenerative disease (notably Parkinson's disease)Potentially essential tremor
05

Safety considerations

Genetic variants linked to familial Parkinson’s disease, conferring risk through endosomal and protein homeostasis disruptionNo therapeutic drugs directly targeting DNAJC13 are in clinical use, so classic drug safety profiles are not relevant.
06

Interacting drugs

None specifically documented as of the current date (2025); DNAJC13 is not a common direct drug target
07

Biomarkers

DNAJC13 mutations (e.g. p.Asn855Ser) as genetic biomarkers for familial Parkinson’s diseaseα-synuclein accumulation linked to DNAJC13 dysfunction has biomarker relevance in Parkinsonism

Beyond the preview

Go deeper on DnaJ heat shock protein family member C13 (DNAJC13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DnaJ heat shock protein family member C13 (DNAJC13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call